The multikinase inhibitor XL-184 (cabozantinib), targeting MET, VEGF-receptor 2 (VEGFR2) and RET, has been evaluated for safety when combined with standard temozolomide chemoradiotherapy in a small cohort of patients with glioblastoma [37], but efficacy data on the combination of RT and MET inhibition in glioblastoma await to be generated. This evidence concerns the gene KDR and glioblastoma.